The article reports on the calls for protection of the biotechnological stocks investments in the U.S. The need to make actions on the uncertainties in pricing biotechnological products are addressed to prevent losses on the industry. Despite potential benefits and commissions offered by the government, the industry is apprehensive on the effects of the volatile pricing on the products.